Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.

Product Highlight - BLACKMORES ESSENTIAL LIVO

01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
  • The support of normal cholesterol, fat metabolism and liver health
  • Improved digestive assistance via the support of fat, carbohydrate and protein metabolism
  • Liver detoxification and antioxidant support
  • Maintenance of normal glucose metabolism
References:
1. Canty D and Zeisel S, Lecithin and Choline in Human Health and Disease, Nutrition Reviews, 1994; 52 (10): 327-339
2.
Health Canada. Choline: Monograph, .September, 2009. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=195&lang=eng (accessed 18th January 2012)
3. Hendler SS. PDR for nutritional supplements 2nd edition. Montvale, Physicians desk reference, 2008
4.
NHMRC, Chromium, Nutrient Reference Values for Australia and New Zealand, Commonwealth of Australia 2006; 235-240
5.
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=64&lang=eng Health Canada Monograph (accessed 23/10/12)

Further information is available in Section 1g and 31b, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.